We are pleased to share that Summa Equity has sold its shares in Olink Holding AB (publ) (“Olink”) to Thermo Fisher Scientific Inc. (“Thermo Fisher”) in relation to their announced public cash tender offer of USD 26.00 per common share in cash, representing USD 26.00 per American Depositary Share (ADS) in cash.

Olink, a Summa Equity Fund II investment, develops and markets its unique technology for protein analysis in human protein biomarker research. Through its leading protein detection technology for analysis of human serum Olink has been an important factor in the progress of precision medicine enabling doctors to use the information about a person’s proteins to prevent, diagnose or treat a range of diseases.

For more information, please read the press release here.

For press inquiries please contact:

Hannah Jacobsen, Partner, COO and Head of Investor Relations
hannah.jacobsen@summaequity.com
+47 93 64 19 60